Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 21:02537176241279547.
doi: 10.1177/02537176241279547. Online ahead of print.

The Antimanic Effect of Endoxifen in Patients with Bipolar Disorder with Renal Comorbidities: Case Series

Astut Kuraria  1 , Rashmi Vishwanath  1 , Anil Kumar M Nagaraj  1 , Savitha Soman  1 , Avinash Kamath  1
Affiliations

The Antimanic Effect of Endoxifen in Patients with Bipolar Disorder with Renal Comorbidities: Case Series

Astut Kuraria et al. Indian J Psychol Med. .

Abstract

The conventional and standard pharmacological approaches in the management of bipolar disorders include mood stabilizers and second-generation antipsychotics. However, renal problems owing to the gold standard mood stabilizer, lithium, is three times that of the general population. As bipolar I disorder (BPD I) is associated with overactive protein kinase C (PKC) intracellular signaling, a novel approach in the management of acute mania/mixed affective states of bipolar disorder includes the use of PKC inhibitors, such as Tamoxifen and its derivative metabolite molecule, Endoxifen. Our objective is to report two cases of bipolar disorder that presented in acute manic episodes, with preexisting renal disease, and safe use of Endoxifen as an adjunct/monotherapy for rapid control of symptoms. According to our study, Endoxifen can be used as an anti-manic agent, either as monotherapy or as an adjunct, in patients with renal disease. It can also be used as an effective cover therapy for bipolar disorder patients requiring steroids for the treatment of renal pathology, though long-term studies are needed to assess the long-term safety and efficacy.

Keywords: Bipolar disorder; Endoxifen; PKC inhibitors; Renal problems.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

References

    1. Vecera CM, Fries GR, Shahani LR, et al.. Pharmacogenomics of lithium response in bipolar disorder. Pharmaceuticals (Basel), 2021; 14(4): 287. - PMC - PubMed
    1. Forty L, Ulanova A, Jones L, et al.. Comorbid medical illness in bipolar disorder. Br J Psychiatry, 2014; 205(6): 465–472. - PMC - PubMed
    1. Saxena A, Scaini G, Bavaresco DV, et al.. Role of protein kinase C in bipolar disorder: A review of the current literature. Mol Neuropsychiatry, 2017. Nov; 3(2): 108–124. - PMC - PubMed
    1. Ahmad A, Sheikh S, Shah T, et al.. Endoxifen, a new treatment option for mania: A double-blind, active-controlled trial demonstrates the antimanic efficacy of Endoxifen. Clin Transl Sci 2016; 9(5): 252–259. Erratum in: Clin Transl Sci. 2017; 10 (2): 117. - PMC - PubMed
    1. Young RC, Biggs JT, Ziegler VE, et al.. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry, 1978; 133: 429–435. - PubMed

LinkOut - more resources